Polymyxin B sulfate and trimethoprim (PBT) are two antibiotics used to treat a wide range of bacterial infections. PBT has been in use for more than 40 years, and is now the most commonly prescribed antibiotic combination in the United States. PBT is effective against most Gram-positive and Gram-negative bacteria, and has been used to treat a variety of infections, including urinary tract infections, skin and soft tissue infections, and respiratory tract infections. In this comprehensive guide, we will discuss the indications, pharmacology, and clinical use of PBT, as well as potential adverse effects and drug interactions.
PBT is indicated for the treatment of a wide range of bacterial infections, including urinary tract infections, skin and soft tissue infections, and respiratory tract infections. It is also approved for the treatment of certain sexually transmitted diseases, including gonorrhea and chlamydia. PBT is also used off-label to treat a variety of other infections, including meningitis, endocarditis, and sepsis.
PBT is a combination of two antibiotics, polymyxin B sulfate and trimethoprim. Polymyxin B is a polypeptide antibiotic derived from the bacterium Bacillus polymyxa. It works by binding to the outer membrane of Gram-negative bacteria, causing disruption of the cell membrane and leakage of intracellular components. Trimethoprim is a synthetic antibiotic that inhibits the synthesis of dihydrofolate reductase, an enzyme involved in the synthesis of folate, a cofactor for the synthesis of nucleic acids. By inhibiting the synthesis of folate, trimethoprim interferes with the synthesis of nucleic acids, preventing bacterial replication.
PBT is generally well tolerated and is effective against most Gram-positive and Gram-negative bacteria, including many resistant strains. It is usually administered orally, although it can also be administered intravenously. The usual dose is one tablet (500mg polymyxin B sulfate and 200mg trimethoprim) taken twice daily for seven to ten days. The dose may need to be adjusted for patients with renal impairment.
As with any medication, PBT can cause adverse effects. The most common side effects include nausea, vomiting, diarrhea, and rash. Other more serious side effects, such as anaphylaxis and Stevens-Johnson syndrome, have been reported in rare cases. PBT can also interact with other medications, including antacids, diuretics, and warfarin. It is important to tell your doctor about all medications you are taking before starting PBT.
Polymyxin B sulfate and trimethoprim (PBT) is a combination antibiotic used to treat a wide range of bacterial infections. It is generally well tolerated and is effective against most Gram-positive and Gram-negative bacteria, including many resistant strains. While PBT is generally safe and effective, it can cause adverse effects and interact with other medications, so it is important to tell your doctor about all medications you are taking before starting PBT. With proper use, PBT can be a powerful tool in the fight against bacterial infections.
1.
Antitumor mRNA-based vaccines show potential against gastric cancer metastasis
2.
How 7,000 steps a day could help reduce your risk of cancer
3.
In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.
4.
Study reveals crucial gaps in oral cancer awareness in Middle East and North Africa
5.
Never in a million years did I think I'd have to limit my chemotherapy.
1.
Understanding Drug-Induced Cardiotoxicity: Mechanisms, Impact, and Future Directions
2.
Imaging in Peritoneal Neoplasms: Diagnostic Advances and Multimodal Treatment Strategies
3.
Exploring the Role of Fecal Leukocytes in Intestinal Health
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part I
4.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
5.
Navigating the Complexities of Ph Negative ALL - Part XIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation